Midday Report: Acadia (ACAD) Shares Climb for August 5

Equities Staff  |

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has gained $1.26 (8.42%) and sits at $16.16, as of 11:45:40 est on August 5.

1,808,201 shares have been traded today.

The Company is up 7.13% over the last 5 days and shares gained 2.29% over the last 30 days.

Acadia expects its next earnings on 2022-08-08.

For technical charts, analysis, and more on Acadia visit the company profile.

About Acadia Pharmaceuticals Inc

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.

To get more information on Acadia Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Acadia Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content